Abstract：
The variability in disease outcome for indolent non-Hodgkin lymphomas (iNHL) and mantle-cell lymphoma (MCL) could be related to single nucleotide polymorphisms (SNPs) in genes that affect immune and inflammatory response. We investigated SNPs that could have a prognostic role for patients receiving bendamustine and rituximab (BR). All samples were genotyped for the IL-2 (rs2069762), IL-10 (rs1800890, rs10494879), VEGFA (rs3025039), IL-8 (rs4073), CFH (rs1065489) and MTHFR (rs1801131) SNPs by allelic discrimination assays using TaqMan SNP Genotyping Assays. We report a long-term follow-up analysis of 79 iNHL and MCL patients that received BR. Overall response rate was 97.5% (CR rate 70.9%). After a median follow-up of 63 months, median PFS and OS were not reached. We report a significant association between SNP in IL-2 (rs2069762) and reduced PFS and OS (p<.0001). We suggest a role for cytokine SNPs in disease outcome, while SNPs seem not related to long-term toxicity or secondary malignancies.
摘要：
无痛性非霍奇金淋巴瘤（iNHL）和套细胞淋巴瘤（MCL）的疾病结果变异性可能与影响免疫和炎症反应的基因中的单核苷酸多态性（SNP）有关。我们调查了可能对接受苯达莫司汀和利妥昔单抗（BR）的患者具有预后作用的SNP。对所有样本进行IL-2基因分型(rs2069762),IL-10(rs1800890,rs10494879),VEGFA(rs3025039),IL-8(rs4073),CFH(rs1065489)和MTHFR(rs1801131)SNP通过使用TaqManSNP基因分型测定的等位基因区分测定。我们报告了79例接受BR的iNHL和MCL患者的长期随访分析。总有效率为97.5%（CR率为70.9%）。经过63个月的中位随访，未达到中位PFS和OS.我们报告了IL-2中的SNP（rs2069762）与降低的PFS和OS（p<0.0001）之间的显着关联。我们建议细胞因子SNP在疾病结果中的作用，而SNP似乎与长期毒性或继发性恶性肿瘤无关。
